



OIPE

RAW SEQUENCE LISTING

DATE: 02/15/2002

PATENT APPLICATION: US/10/058,821

TIME: 15:27:36

Input Set : A:\401c12.app

Output Set: N:\CRF3\02152002\J058821.raw

3 <110> APPLICANT: Blaschuk, Orest W.
 4 Gour, Barbara J.
 5 Farookhi, Riaz
 7 <120> TITLE OF INVENTION: COMPOUNDS AND METHODS FOR CANCER THERAPY
 9 <130> FILE REFERENCE: 100086.401C12
 C--> 11 <140> CURRENT APPLICATION NUMBER: US/10/058,821
 12 <141> CURRENT FILING DATE: 2002-01-29
 14 <160> NUMBER OF SEQ ID NOS: 58
 16 <170> SOFTWARE: PatentIn Ver. 2.0
 18 <210> SEQ ID NO: 1
 19 <211> LENGTH: 108
 20 <212> TYPE: PRT
 21 <213> ORGANISM: Homo sapiens
 23 <400> SEQUENCE: 1
 24 Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro
 25 1 5 10 15
 27 Phe Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu
 28 20 25 30
 30 Ser Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr
 31 35 40 45
 33 Gly Ile Phe Ile Leu Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys
 34 50 55 60
 36 Pro Leu Asp Arg Glu Gln Ile Ala Arg Phe His Leu Arg Ala His Ala
 37 65 70 75 80
 39 Val Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile
 40 85 90 95
 42 Asn Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe
 43 100 105
 46 <210> SEQ ID NO: 2
 47 <211> LENGTH: 108
 48 <212> TYPE: PRT
 49 <213> ORGANISM: Mus musculus
 51 <400> SEQUENCE: 2
 52 Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro
 53 1 5 10 15
 55 Phe Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu
 56 20 25 30
 58 Ser Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr
 59 35 40 45
 61 Gly Ile Phe Ile Ile Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys
 62 50 55 60
 64 Pro Leu Asp Arg Glu Leu Ile Ala Arg Phe His Leu Arg Ala His Ala
 65 65 70 75 80

ENTERED

RAW SEQUENCE LISTING

DATE: 02/15/2002

PATENT APPLICATION: US/10/058,821

TIME: 15:27:36

Input Set : A:\401c12.app

Output Set: N:\CRF3\02152002\J058821.raw

```

67 Val Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile
68           85           90           95
70 Asn Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe
71           100           105
74 <210> SEQ ID NO: 3
75 <211> LENGTH: 108
76 <212> TYPE: PRT
77 <213> ORGANISM: Bos taurus
79 <400> SEQUENCE: 3
80 Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro
81   1           5           10           15
83 Phe Pro Gln Glu Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu
84           20           25           30
86 Ser Leu Arg Tyr Ser Val Thr Gly Pro Gly Ala Asp Gln Pro Pro Thr
87           35           40           45
89 Gly Ile Phe Ile Ile Asn Pro Ile Ser Gly Gln Leu Ser Val Thr Lys
90           50           55           60
92 Pro Leu Asp Arg Glu Leu Ile Ala Arg Phe His Leu Arg Ala His Ala
93   65           70           75           80
95 Val Asp Ile Asn Gly Asn Gln Val Glu Asn Pro Ile Asp Ile Val Ile
96           85           90           95
98 Asn Val Ile Asp Met Asn Asp Asn Arg Pro Glu Phe
99           100           105
102 <210> SEQ ID NO: 4
103 <211> LENGTH: 108
104 <212> TYPE: PRT
105 <213> ORGANISM: Homo sapiens
107 <400> SEQUENCE: 4
108 Asp Trp Val Val Ala Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro
109   1           5           10           15
111 Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr
112           20           25           30
114 Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu
115           35           40           45
117 Gly Val Phe Ala Val Glu Lys Glu Thr Gly Trp Leu Leu Asn Lys
118           50           55           60
120 Pro Leu Asp Arg Glu Glu Ile Ala Lys Tyr Glu Leu Phe Gly His Ala
121   65           70           75           80
123 Val Ser Glu Asn Gly Ala Ser Val Glu Asp Pro Met Asn Ile Ser Ile
124           85           90           95
126 Ile Val Thr Asp Gln Asn Asp His Lys Pro Lys Phe
127           100           105
130 <210> SEQ ID NO: 5
131 <211> LENGTH: 108
132 <212> TYPE: PRT
133 <213> ORGANISM: Mus musculus
135 <400> SEQUENCE: 5
136 Glu Trp Val Met Pro Pro Ile Phe Val Pro Glu Asn Gly Lys Gly Pro
137   1           5           10           15

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/058,821

DATE: 02/15/2002

TIME: 15:27:36

Input Set : A:\401c12.app

Output Set: N:\CRF3\02152002\J058821.raw

```

139 Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr
140           20           25           30
142 Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu
143           35           40           45
145 Gly Val Phe Thr Ile Glu Lys Glu Ser Gly Trp Leu Leu His Met
146           50           55           60
148 Pro Leu Asp Arg Glu Lys Ile Val Lys Tyr Glu Leu Tyr Gly His Ala
149           65           70           75           80
151 Val Ser Glu Asn Gly Ala Ser Val Glu Glu Pro Met Asn Ile Ser Ile
152           85           90           95
154 Ile Val Thr Asp Gln Asn Asp Asn Lys Pro Lys Phe
155           100          105
158 <210> SEQ ID NO: 6
159 <211> LENGTH: 108
160 <212> TYPE: PRT
161 <213> ORGANISM: Homo sapiens
163 <400> SEQUENCE: 6
164 Asp Trp Val Ile Pro Pro Ile Ser Cys Pro Glu Asn Glu Lys Gly Pro
165   1           5           10           15
167 Phe Pro Lys Asn Leu Val Gln Ile Lys Ser Asn Lys Asp Lys Glu Gly
168           20           25           30
170 Lys Val Phe Tyr Ser Ile Thr Gly Gln Gly Ala Asp Thr Pro Pro Val
171           35           40           45
173 Gly Val Phe Ile Ile Glu Arg Glu Thr Gly Trp Leu Lys Val Thr Glu
174           50           55           60
176 Pro Leu Asp Arg Glu Arg Ile Ala Thr Tyr Thr Leu Phe Ser His Ala
177           65           70           75           80
179 Val Ser Ser Asn Gly Asn Ala Val Glu Asp Pro Met Glu Ile Leu Ile
180           85           90           95
182 Thr Val Thr Asp Gln Asn Asp Asn Lys Pro Glu Phe
183           100          105
186 <210> SEQ ID NO: 7
187 <211> LENGTH: 108
188 <212> TYPE: PRT
189 <213> ORGANISM: Mus musculus
191 <400> SEQUENCE: 7
192 Asp Trp Val Ile Pro Pro Ile Ser Cys Pro Glu Asn Glu Lys Gly Glu
193   1           5           10           15
195 Phe Pro Lys Asn Leu Val Gln Ile Lys Ser Asn Arg Asp Lys Glu Thr
196           20           25           30
198 Lys Val Phe Tyr Ser Ile Thr Gly Gln Gly Ala Asp Lys Pro Pro Val
199           35           40           45
201 Gly Val Phe Ile Ile Glu Arg Glu Thr Gly Trp Leu Lys Val Thr Gln
202           50           55           60
204 Pro Leu Asp Arg Glu Ala Ile Ala Lys Tyr Ile Leu Tyr Ser His Ala
205           65           70           75           80
207 Val Ser Ser Asn Gly Glu Ala Val Glu Asp Pro Met Glu Ile Val Ile
208           85           90           95
210 Thr Val Thr Asp Gln Asn Asp Asn Arg Pro Glu Phe

```

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/10/058,821

DATE: 02/15/2002
 TIME: 15:27:36

Input Set : A:\401c12.app
 Output Set: N:\CRF3\02152002\J058821.raw

211 100 105
 214 <210> SEQ ID NO: 8
 215 <211> LENGTH: 5
 216 <212> TYPE: PRT
 217 <213> ORGANISM: Unknown
 219 <220> FEATURE:
 220 <221> NAME/KEY: MOD_RES
 221 <222> LOCATION: (2)
 222 <223> OTHER INFORMATION: Where Xaa is any amino acid
 224 <220> FEATURE:
 225 <223> OTHER INFORMATION: Description of Unknown Organism: Cadherin Calcium
 226 Binding Motif
 228 <400> SEQUENCE: 8
 229 Asp Xaa Asn Asp Asn
 230 1 5
 233 <210> SEQ ID NO: 9
 234 <211> LENGTH: 4
 235 <212> TYPE: PRT
 236 <213> ORGANISM: Unknown
 238 <220> FEATURE:
 239 <223> OTHER INFORMATION: Description of Unknown Organism: Cadherin Calcium
 240 Binding Motif
 242 <400> SEQUENCE: 9
 243 Leu Asp Arg Glu
 244 1
 247 <210> SEQ ID NO: 10
 248 <211> LENGTH: 5
 249 <212> TYPE: PRT
 250 <213> ORGANISM: Artificial Sequence
 252 <220> FEATURE:
 253 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic Peptide
 254 with Classical Cell Adhesion Recognition Sequence
 256 <220> FEATURE:
 257 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal
 258 modification such as acetyl or alkoxybenzyl group
 259 and/or C-terminal modifications such as amide or
 260 ester group
 262 <400> SEQUENCE: 10
 263 Cys His Ala Val Cys
 264 1 5
 267 <210> SEQ ID NO: 11
 268 <211> LENGTH: 5
 269 <212> TYPE: PRT
 270 <213> ORGANISM: Artificial Sequence
 272 <220> FEATURE:
 273 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic
 274 control peptide
 276 <220> FEATURE:
 277 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal

RAW SEQUENCE LISTING

DATE: 02/15/2002

PATENT APPLICATION: US/10/058,821

TIME: 15:27:36

Input Set : A:\401c12.app

Output Set: N:\CRF3\02152002\J058821.raw

```

278      modification such as acetyl or alkoxybenzyl group
279      and/or C-terminal modifications such as amide or
280      ester group
282 <400> SEQUENCE: 11
283 Cys His Gly Val Cys
284   1           5
287 <210> SEQ ID NO: 12
288 <211> LENGTH: 5
289 <212> TYPE: PRT
290 <213> ORGANISM: Artificial Sequence
292 <220> FEATURE:
293 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic
294      peptide with cadherin cell adhesion recognition
295      sequence
297 <220> FEATURE:
298 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal
299      modification such as acetyl or alkoxybenzyl group
300      and/or C-terminal modifications such as amide or
301      ester group
303 <400> SEQUENCE: 12
304 Lys His Ala Val Asp
305   1           5
307 <210> SEQ ID NO: 13
308 <211> LENGTH: 5
309 <212> TYPE: PRT
310 <213> ORGANISM: Artificial Sequence
312 <220> FEATURE:
313 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic
314      peptide with cadherin cell adhesion recognition
315      sequence
317 <220> FEATURE:
318 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal
319      modification such as acetyl or alkoxybenzyl group
320      and/or C-terminal modifications such as amide or
321      ester group
323 <400> SEQUENCE: 13
324 Asp His Ala Val Lys
325   1           5
328 <210> SEQ ID NO: 14
329 <211> LENGTH: 5
330 <212> TYPE: PRT
331 <213> ORGANISM: Artificial Sequence
333 <220> FEATURE:
334 <223> OTHER INFORMATION: Description of Artificial Sequence: Cyclic
335      peptide with classical cadherin cell adhesion
336      recognition sequence
338 <220> FEATURE:
339 <223> OTHER INFORMATION: Cyclic Peptide may comprise N-terminal
340      modification such as acetyl or alkoxybenzyl group

```

→ Use of n and/or Xaa has been detected in the Sequence Listing.
 Review the Sequence Listing to insure a corresponding
 definition is presented in the <220> to <223> fields of
 each sequence using n or Xaa.

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/058,821

DATE: 02/15/2002

TIME: 15:27:37

Input Set : A:\401c12.app

Output Set: N:\CRF3\02152002\J058821.raw

L:11 M:270 C: Current Application Number differs, Wrong Format
L:229 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:789 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:837 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:1072 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47
L:1098 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
L:1124 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
L:1150 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
L:1178 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51